A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan

Journal of the Chinese Medical Association

Volumn 68, Issue 7, 2005, Pages 307-314

  Cheng, Ming Huei ^a,b   Yu, Bill Ken Jen ^a,b,c,d   Chang, Sheng Ping ^a,b   Wang, Peng Hui ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Danazol; Endometriosis; Nafarelin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DANAZOL; LIPID; NAFARELIN; NAFARELIN ACETATE;

ABDOMINAL PAIN; ACNE; ADULT; ARTICLE; ASTHENIA; BODY WEIGHT DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; DYSPAREUNIA; ENDOMETRIOSIS; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; LAPAROSCOPY; LARYNX DISORDER; LEUKORRHEA; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; MUSCLE HYPERTONIA; MUSCLE SPASM; PAIN; PARALLEL DESIGN; PATIENT MONITORING; PELVIS PAIN SYNDROME; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TAIWAN; THORAX PAIN; VAGINA BLEEDING; VAGINA DISEASE; VAGINITIS; WEIGHT GAIN;

EID: 21844437623     PISSN: 17264901     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1726-4901(09)70166-2     Document Type: Article

References (17)

1. Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. N Engl J Med 1988;318:485-9.
2. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364:1789-99.
3. Wang PH, Juang CM, Chao HT, Yu KJ, Yuan CC, Ng HT. Wound endometriosis: risk factor evaluation and treatment. J Chin Med Assoc 2003;66:113-9.
4. Garry R. The effectiveness of laparoscopic excision of endometriosis. Curr Opin Obstet Gynecol 2004;16:299-303.
5. Henzl MR. Gonadotropin-releasing hormone (GnRH) agonists in the management of endometriosis: a review. Clin Obstet Gynecol 1988;31:840-56.
6. Schroder AE, Diedrich K, Ludwig M. Medical management of endometriosis: a systematic review. Drugs 2004;7:451-63.
7. Allen JK, Fraser IS. Cholesterol, high density lipoprotein and danazol. J Clin Endocrinol Metab 1981;53:149-52.
8. Burry KA, Patton PE, Illingworth DR. Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol. Am J Obstet Gynecol 1989;160:1454-61.
9. Fahraeus L. Profound alterations of the lipoprotein metabolism during danazol treatment in premenopausal women. Fertil Steril 1984;42:52-7.
10. Valimaki M, Nilsson CG, Roine R, Ylikorkala O. Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis. J Clin Endocrinol Metab 1989;69:1097-103.
11. Henzl MR, Kwei L. Efficacy and safety of nafarelin in the treatment of endometriosis. Am J Obstet Gynecol 1990;162:570-4.
12. Chaplin MD. Bioavailability of nafarelin in healthy volunteers. Am J Obstet Gynecol 1992;166:762-5.
13. Chan RL, Henzl MR, LePage ME. Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. Am Pharmacol Ther 1998;44:275-82.
14. Anonymous. Revised American Fertility Society classification of endometriosis: 1985. Fertil Steril 1985;143:351-2.
15. Burry KA. Nafarelin in the management of endometriosis: quality of life assessment. Am J Obstet Gynecol 1992;166:735-9.
16. Henzl MR. Role of nafarelin in the management of endometriosis. J Reprod Med 1989;34:1021-4.
17. Wang PH, Yang TS, Lee WL, Chao HT, Chang SP, Yuan CC. Treatment of infertile women with adenomyosis with a conservative microsurgical technique and a gonadotropin-releasing hormone agonist. Fertil Steril 2000;73:1061-2.